Level of DNA-fragmentation Before and After Antioxidant-based Therapies in Male Infertility

Sponsor
Janna Pape (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06050031
Collaborator
(none)
78
25

Study Details

Study Description

Brief Summary

The investigators will investigate the effect of antioxidants and lifestyle factors on the level of oxidative stress. As oxidative stress cannot be directly measured, it will be approximated by the DNA fragmentation index (DFI) which reflects the level of DNA damage in sperm caused by oxidative stress.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Intake of antioxidant supplement

Detailed Description

This is a one-site prospective exploratory study at the University Clinic for Gynaecological Endocrinology and Reproductive Medicine in Bern. On total 78 men with male infertility will be recruited.

The primary objective of the study is to assess the effectiveness of 3 months of antioxidant-based therapy on changing patients' DFI level.

The objective of the study is to assess the effect of 3 months of antioxidant-based therapy on the level of DFI. We are primarily interested in testing whether the treatment effectiveness (i.e. the change in DFI level) depends on the initial level (i.e. before treatment) and treatment adherence.

The data will be collected by the physicians and added to the REDcap study registry. Access to the total data set is only permitted for the principal investigator.

Study Design

Study Type:
Observational
Anticipated Enrollment :
78 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Level of DNA-fragmentation Before and After Antioxidant-based Therapies in Male Infertility: An Observational Study on Factors Influencing the Treatment Effects
Anticipated Study Start Date :
Nov 1, 2023
Anticipated Primary Completion Date :
Jun 1, 2025
Anticipated Study Completion Date :
Dec 1, 2025

Outcome Measures

Primary Outcome Measures

  1. DFI [At baseline and after three months of antioxidant-treatment]

    DNA-fragmentation measured by sperm-chromatin-structure-assay (SCSA)

Secondary Outcome Measures

  1. Sperm concentration [At baseline and after three months of antioxidant-treatment]

    Sperm concentration [10^6/mL]

  2. Sperm motility [At baseline and after three months of antioxidant-treatment]

    Total sperm progressive motility [%] Oxidation-reduction potential [mV/10-6 sperm/mL]

  3. Oxidation-reduction potential in ejaculate [At baseline and after three months of antioxidant-treatment]

    Oxidation-reduction potential [mV/10-6 sperm/mL]

  4. Alcohol consumption [At baseline and during the three months of antioxidant-treatment]

    Alcohol consumption [unit per week]

  5. BMI [At baseline and after the three months of antioxidant-treatment]

    BMI [kg/m2]

  6. Smoking [At baseline and during the three months of antioxidant-treatment]

    Cigarette consumption [number of cigarettes per week]

  7. Treatment adherence [During three months of antioxidants]

    Averaged missing capsules per week (100%, 75%, 50%, 25%) during treatment

  8. Implantation rate [10-12 days after timed intercourse, insemination or embryo transfer in the first treatment cycle after the antioxidant treatment]

    Endocrine pregnancy by measuring hCG in blood sample on day 10-12 after timed intercourse, insemination or embryo transfer

  9. Clinical pregnancy rate [5 weeks after timed intercourse, insemination or embryo transfer in the first treatment cycle after the antioxidant treatment]

    Clinical pregnancy confirmed by ultrasound, 5 weeks after timed intercourse, insemination or embryo transfer

  10. Live birth rate [9 months after timed intercourse, insemination or embryo transfer in the first treatment cycle after the antioxidant treatment]

    Birth of a living baby nine months after timed intercourse, insemination or embryo transfer

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 60 Years
Sexes Eligible for Study:
Male
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Willing to participate

  • Written consent

  • Men with infertility problems who want to start an infertility treatment with their partner

Exclusion Criteria:
  • No measurement of DNA fragmentation possible

  • Intake of prescribed medications

  • Exposure to toxins

  • Chronic diseases

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Janna Pape

Investigators

  • Study Chair: Michael von Wolff, Prof, Universitätsklinik fur Frauenheilkunde, Inselspital Bern

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Janna Pape, Principal Investigator, Dr. med. Janna Pape, Universitätsklinik fur Frauenheilkunde, Inselspital Bern
ClinicalTrials.gov Identifier:
NCT06050031
Other Study ID Numbers:
  • 2023-00611
First Posted:
Sep 22, 2023
Last Update Posted:
Sep 22, 2023
Last Verified:
Sep 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Janna Pape, Principal Investigator, Dr. med. Janna Pape, Universitätsklinik fur Frauenheilkunde, Inselspital Bern
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 22, 2023